MarketPulse
C

$CMPS

7 articles found
7 positive
0 negative
0 neutral
Investing.comInvesting.com··Nathan Reiff

Trump's Psychedelic Order Ignites Biotech Rally, But Valuations Raise Caution

Trump's April 2026 executive order grants FDA priority vouchers to psychedelic biotech firms, triggering stock surges for Compass Pathways, AtaiBeckley, and Definium Therapeutics amid speculative valuations.
DFTXCMPSPSILbiotechclinical trials
Investing.comInvesting.com··Jeffrey Neal Johnson

Psychedelics Eclipse Cannabis as Wall Street's Alternative Medicine Darling

Executive order fast-tracks psychedelics, spurring 40% surges in Compass Pathways and Atai Beckley, while cannabis operators like Curaleaf transition to stable income plays.
CMPSIIPRIIPRpAMSOSbiotechshort squeeze
The Motley FoolThe Motley Fool··Howard Smith

Compass Pathways Surges 40% on White House Push for Psychedelic Drug Approvals

Compass Pathways stock surges 40% following White House Executive Order accelerating FDA approval of its COMP360 psychedelic therapy for treatment-resistant depression.
CMPSFDA approvaltreatment-resistant depression
The Motley FoolThe Motley Fool··Matthew Benjamin

Trump's Psychedelic Fast-Track Order Opens New Frontier for FDA Approvals

Trump executive order accelerates psychedelic drug approvals from 6-10 months to 1-2 months, allocates $50M for research, benefiting biotech companies.
DFTXCMPStreatment-resistant depressionmental health
The Motley FoolThe Motley Fool··Motley Fool Staff

Psychedelic Therapy Emerges as Disruptive Mental Health Treatment Model

Psychedelic therapy advances as clinical treatment for depression and PTSD, with companies like Compass Pathways pursuing FDA approvals. The investment opportunity centers on $10,000-$20,000 treatment services rather than drugs.
JNJABBVCMPStreatment-resistant depressionpsilocybin
BenzingaBenzinga··Prnewswire

Psilocybin Pipeline Expands as Regulatory Support Strengthens for CNS Applications

Psilocybin gains regulatory momentum with first Phase 3 success in treatment-resistant depression. DEA increases production quota 67%, while five pharma companies advance psychedelic programs across multiple CNS indications.
CMPSRLMDANROAXSMFDA approvalPhase 3 trials
The Motley FoolThe Motley Fool··Howard Smith

Compass Pathways Surges on Positive Phase 3 Psilocybin Trial Results

Compass Pathways stock surged 44% after positive Phase 3 trial results for psilocybin depression therapy. FDA application expected by end of 2024.
CMPSFDA approvaltreatment-resistant depression